Semaglutide (10 mg) is a structurally engineered analog of glucagon-like peptide-1 (GLP-1), designed for extended observation of peptide-driven signaling in controlled research environments. It incorporates amino acid substitutions and a lipid-based modification to enhance molecular stability and reduce susceptibility to rapid enzymatic degradation.

With a molecular weight of 4113.6 g/mol, Semaglutide is supplied as a ≥95% pure, lyophilized powder in a sealed research-grade vial. These structural features enable researchers to evaluate sustained receptor interactions, providing a consistent model for studying time-dependent signaling activity.

In research, Semaglutide (10 mg) has been utilized to examine how prolonged peptide exposure influences metabolic coordination, receptor responsiveness, and downstream cellular communication under controlled conditions.

Semaglutide (10 mg) Key Features & Specs

• Subcategory: Weight Loss & Metabolic Peptides
• Strength: 10 mg
• CAS: 910463-68-2
• Chemical Formula: C₁₈₇H₂₉₁N₄₅O₅₉
• Molecular Weight: 4113.6 g/mol
• Peptide Sequence: H-His-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys(AEEAc-AEEAc-γ-Glu-17-carboxyheptadecanoyl)-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-OH
• Synonyms: NN9535

For laboratory research use only.

Semaglutide (10 mg) Research Uses

Semaglutide (10 mg) is being researched for its role in GLP-1 receptor–mediated signaling and related metabolic processes. Studies often focus on how this peptide influences receptor binding, intracellular signaling, and hormone-regulated cellular responses.

In controlled settings, it is used to investigate second-messenger systems, such as cAMP-related signaling, as well as broader endocrine communication pathways. Ongoing research aims to evaluate how peptide analogs influence metabolic coordination and signaling duration.

Semaglutide (10 mg) Insights & Observed Findings

Studies using Semaglutide (10 mg) typically involve structured dosing regimens tailored to specific in vitro or preclinical models. Observations focus on signaling duration, receptor engagement, and measurable changes in metabolic markers.

Research indicates that its modified structure enables sustained interactions in experimental systems, allowing researchers to assess time-dependent responses, such as receptor desensitization and signaling persistence. Outcomes can vary based on model design, analytical methods, and study duration.

Semaglutide (10 mg) Handling & Storage

• Store at 2–8°C for short-term use.
• For extended storage, store at ≤–20°C.
• Keep the vial tightly sealed and protected from light to maintain sample integrity.
• Minimize exposure to moisture and environmental contaminants.
• Allow the vial to equilibrate to room temperature before opening to reduce condensation.
• After reconstitution, store the solution at 2–8°C.
• Follow standard laboratory procedures.
• Avoid repeated freeze-thaw cycles.

Compliance Notice: This product is intended for laboratory research use only and is not approved for human or veterinary use. It is not intended for diagnostic, therapeutic, or clinical applications. Any reference to biological activity or potential effects is based solely on preclinical or in-vitro findings and should not be interpreted as validated clinical outcomes. Researchers are responsible for ensuring proper handling, storage, and disposal in accordance with institutional, federal, and international guidelines.

References

1. Lau J, Bloch P, Schäffer L, et al. Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide. J Med Chem. 2015;58(18):7370-7380. doi:10.1021/acs.jmedchem.5b00726
2. Liu QK. Mechanisms of action and therapeutic applications of GLP-1 and dual GIP/GLP-1 receptor agonists. Front Endocrinol (Lausanne). 2024;15:1431292. Published 2024 Jul 24. doi:10.3389/fendo.2024.1431292
3. Loomba R, Abdelmalek MF, Armstrong MJ, et al. Semaglutide 2·4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial. Lancet Gastroenterol Hepatol. 2023;8(6):511-522. doi:10.1016/S2468-1253(23)00068-7
4. Mahapatra MK, Karuppasamy M, Sahoo BM. Semaglutide, a glucagon like peptide-1 receptor agonist with cardiovascular benefits for management of type 2 diabetes. Rev Endocr Metab Disord. 2022;23(3):521-539. doi:10.1007/s11154-021-09699-1
5. Knudsen LB, Lau J. The Discovery and Development of Liraglutide and Semaglutide. Front Endocrinol (Lausanne). 2019;10:155. Published 2019 Apr 12. doi:10.3389/fendo.2019.00155